go to medicines.ie homepage
  • Home  |  
  • About  |  
  • Links  |  
  • Help
Font Size
Search for:  
select
select
  • SPCs and PILs
  • SPCs Only
  • PILs Only
  Advanced Search
  • What's
    New
      
  • Browse
    Medicines
      
  • Browse
    Active Ingredients
      
  • Browse
    Companies
      
  • Codes
    of Practice
      
  • Adverse
    Reaction Reporting

Boehringer Ingelheim Limited

Boehringer Ingelheim Limited
Corrig Court, Corrig Road, Sandyford Industrial Estate, Dublin 18,
Telephone: +353 1 2959620
Fax: +353 1 2959624
Medical Information e-mail: Medinfo@dbl.boehringer-ingelheim.com
Summary of Product Characteristics last updated on medicines.ie: 11/07/2011
SPC Twynsta 80 mg/10 mg tablets

When a pharmaceutical company changes an SPC or PIL, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 11/07/2011 and displayed until Current
Reasons for adding or updating:
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.3 - Preclinical safety data
  • Change to section 10 - Date of revision of the text
Date of revision of text on the SPC:   14-Jun-2011
Legal Category:   Product subject to medical prescription which may be renewed (B)

Free-text change information supplied by the pharmaceutical company



Section 4.5 Interaction with Other Medicinal Products and Other Forms of Interaction

A new paragraph regarding grapefruit and grapefruit juice has been added as a final paragraph to the Concomitant use requiring caution sub-heading under the Interactions linked to amlodipine sub-heading of this section.

 

What previously was the last paragraph regarding concomitant administration of 240 ml of grapefruit juice in the Concomitant use to be taken into account sub-heading of the Interactions linked to amlodipine sub-heading has been deleted from this section.

 

Section 4.6 Fertility, Pregnancy and Lactation

The first four sentences of the Fertility sub-heading of this section have been added as new text.

 

Section 4.8 Undesirable Effects

New adverse reaction details [Rare: Hypoglycaemia (in diabetic patients)] have been added to the Metabolism and Nutrition Disorders frequency grouping for Telmisartan in this section.

 

A figure 2 (in superscript) has been added to the end of the Rare adverse reaction details of the Hepato-biliary Disorders frequency grouping for Telmisartan.  Subsequent details regarding hepatic function abnormal/liver disorder and Japanese patients has been added as supporting text at the end of the Telmisartan disorders frequency grouping list.

 

The text … (with fatal outcome) has been added to the Rare adverse reaction details of the Skin and Subcutaneous Tissues Disorders frequency grouping for Telmisartan.

 

The text Peripheral neuropathy has been deleted from the Very Rare adverse reaction details of the Nervous System Disorders frequency grouping for Amlodipine, as has the Uncommon adverse reaction details. 

 

Section 5.3 Preclinical Safety Data

The last but one paragraph of the Telmisartan sub-heading of this section regarding teratogenic effect has been reworded/amended including deletion of the reference to animal studies.

 

Section 10 Date of Revision of the Text

The date of 14 June 2011 has been added to this section.

Updated on 01/01/2011 and displayed until 11/07/2011
Reasons for adding or updating:
  • New SPC for new product
Date of revision of text on the SPC:  
Legal Category:   Product subject to medical prescription which may be renewed (B)

Free-text change information supplied by the pharmaceutical company

None provided

Document Links

 
  View all medicines
from this company
View Document
Bookmark and Share

Active Ingredients

 
   Telmisartan
   Amlodipine besilate

Versions

 
11/07/2011 to Current
01/01/2011 to 11/07/2011
  • Terms & Conditions | 
  • Accessibility | 
  • Privacy Statement | 
  • Contact Us

Registered Address: Franklin House, 140 Pembroke Road, Dublin 4, Ireland
Registered Number: 254776
Tel: (353 1) 6603350 Fax: (353 1) 6686672 Email: info@ipha.ie

This website is certified by Health On the Net Foundation. Click to verify.

This site complies with the HONcode standard for trustworthy health information: verify here.

logo